N4 Pharma PLC
LSE:N4P
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.375
0.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
N4 Pharma PLC
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
|
N4 Pharma PLC
LSE:N4P
|
4.4m GBP |
-16 920%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
44%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
496.6B USD |
27%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
259.2B CHF |
34%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212B GBP |
24%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
208.2B CHF |
33%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
251.4B USD |
38%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
42%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
209B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
143.2B USD |
29%
|
N4 Pharma PLC
Glance View
N4 Pharma Plc is a pharmaceutical company, which engages in the reformulation of existing drugs and vaccines. The company is headquartered in Derby, Derbyshire and currently employs 5 full-time employees. The company went IPO on 2005-06-07. The firm is engaged in engaged in the development of mesoparticulate silica delivery systems to improve the cellular delivery and potency of vaccines. The company is focused on developing a delivery system for vaccines and cancer treatments using its silica nanoparticle delivery system called Nuvec. Nuvec is a non-viral adjuvant delivery system that has the potential to revolutionize vaccines and cancer treatments. The company is focused on development and commercialization of medicines via its delivery system.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on N4 Pharma PLC's most recent financial statements, the company has Operating Margin of -16 919.7%.